Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ARDX
- Price
- 4.46
- Stock movement up
- +0.21 (4.94%)
- Company name
- Ardelyx Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.06B
- Ent value
- 1.22B
- Price/Sales
- 4.19
- Price/Book
- 6.67
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -40.57%
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -28.61%
- 1 year return
- -37.45%
- 3 year return
- 60.44%
- 5 year return
- -3.65%
- 10 year return
- -9.59%
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ARDX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 4.19 |
| Price to Book | 6.67 |
| EV to Sales | 4.84 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 236.85M |
| EPS (TTM) | -0.31 |
| FCF per share (TTM) | -0.27 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 251.85M |
| Gross profit (TTM) | 213.48M |
| Operating income (TTM) | -64.06M |
| Net income (TTM) | -72.58M |
| EPS (TTM) | -0.31 |
| EPS (1y forward) | -0.17 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 84.76% |
| Operating margin (TTM) | -25.44% |
| Profit margin (TTM) | -28.82% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 47.43M |
| Net receivables | 53.20M |
| Total current assets | 284.10M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 4.65M |
| Total assets | 367.86M |
| Accounts payable | 15.82M |
| Short/Current long term debt | 104.49M |
| Total current liabilities | 70.50M |
| Total liabilities | 209.57M |
| Shareholder's equity | 158.30M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -63.34M |
| Capital expenditures (TTM) | 461.00K |
| Free cash flow (TTM) | -63.80M |
| Dividends paid (TTM) | 25.89M |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -45.85% |
| Return on Assets | -19.73% |
| Return on Invested Capital | -27.48% |
| Cash Return on Invested Capital | -24.15% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.22 |
| Daily high | 4.50 |
| Daily low | 4.17 |
| Daily Volume | 6.12M |
| All-time high | 32.89 |
| 1y analyst estimate | 10.78 |
| Beta | 0.91 |
| EPS (TTM) | -0.31 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 30 Apr 2025 |
Downside potential
Loading...
Downside potential data
| ARDX | S&P500 | |
| Current price drop from All-time high | -86.44% | -12.89% |
| Highest price drop | -98.45% | -56.47% |
| Date of highest drop | 14 Jun 2022 | 9 Mar 2009 |
| Avg drop from high | -76.77% | -11.07% |
| Avg time to new high | 181 days | 12 days |
| Max time to new high | 2605 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.06B
Marketcap category
Small-cap
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Employees
267
Website
Investor relations
-
SEC filings
CEO
Michael G. Raab
Country
USA
City
Fremont
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
Ardelyx, Inc. (NASDAQ:ARDX) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ETCompany ParticipantsCaitlin Lowie - Vice President of Corporate...
November 1, 2024
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
Ardelyx's tenapanor targets IBS-C and hyperphosphatemia in CKD patients, showing strong revenue growth. Read why I downgrade ARDX stock from buy to hold.
September 25, 2024
Ardelyx, Inc. (NASDAQ:ARDX) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ETCompany ParticipantsCaitlin Lowie - Vice President of Corporate...
August 2, 2024
iO Charts is a Seeking Alpha partnerNext page